The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.
Study Type
OBSERVATIONAL
Enrollment
412
Lenvatinib capsule.
Eisai Trial Site #1
Osaka, Japan
Eisai Trial Site #2
Tokyo, Japan
Overall Survival (OS)
OS is calculated as the period from the day of starting administration to the day of death from any cause.
Time frame: From date of study drug administration until date of death from any cause (approximately 2.8 years)
Presence or absence of factors with a possible influence on OS
Factor analysis is performed according to the category of participant background (aetiology of chronic liver disease, baseline alpha-fetoprotein concentration etc), lenvima administration status and treatment situation before and after administration of lenvima, and factors affecting OS are examined. Appropriate statistical methods (Cox regression analysis, etc.) will be used to examine the relationship of OS with various factors in order to identify the factors affecting survival.
Time frame: From date of study drug administration until date of death from any cause (approximately 2.8 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.